Binod Dhakal, MD

Associate Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English, Nepali, Hindi

Cancer Center - Froedtert Hospital

(414) 805-0505

Education

MD - Doctor of Medicine

Biography

Binod Dhakal, MD, MS, is Assistant Professor of Medicine, at the Medical College of Wisconsin, Division of Hematology, specializing in multiple myeloma and plasma cell disorders. He graduated from Manipal College of Medical Sciences, Pokhara Nepal in 2004, completed Internal Medicine Residency at Saint Francis Hospital Evanston Illinois, and a fellowship in hematology/oncology at the Medical College of Wisconsin, where he also served as a Chief Fellow. Prior to joining the fellowship, he was Assistant Professor of Medicine at the Medical College in Wisconsin in the Division of General Internal Medicine. He has authored numerous publications, including journal articles, meeting abstracts and book chapters. He has also won several awards during his fellowship which include the American Society of Clinical Oncology (ASCO) Merit Award; Medical College of Wisconsin Affiliated Hospitals (MCWAH) research award; Central Society for Clinical and Translational Research (CSCTR) best oral abstract and travel trainee award; American Society for Blood and Marrow Transplantation (ASBMT) clinical research training course; and, Outstanding Medical School Teacher award. Additionally, he was the recipient of the Mazie Froedtert Willms and Sue Froedtert Cancer Scholarship, and obtained his Master’s Degree in Clinical and Translational Science.

Research Interests

Dr. Dhakal's current research interests focus on novel drug treatments for patients with multiple myeloma and related plasma cell disorders by designing and conducting early phase clinical trials.

Safety of Dapsone for Pneumocystis Jiroveci Pneumonia Prophylaxis in Patients With Multiple Myeloma.

(Kim M, Arabi J, McCoy C, D'Souza A, Chhabra S, Abid MB, Thapa B, Dhakal B.) Clin Lymphoma Myeloma Leuk. 2024 Nov;24(11):804-807 PMID: 39043500 SCOPUS ID: 2-s2.0-85200365330 07/24/2024
Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma.

(Yohay S, Oloyede T, Kim S, Fang X, Dhakal B, Aijaz A, Mohan M, Narra R, Pasquini M, D'Souza A, Hamadani M, Freeman CL, Akhtar OS.) Br J Haematol. 2024 Oct 13 PMID: 39396814 SCOPUS ID: 2-s2.0-85206072300 10/14/2024
Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database.

(Dhakal B, Einsele H, Schecter JM, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Nair S, He J, Kharat A, Cost P, Valluri S, Yong K.) Blood Adv. 2024 Oct 08;8(19):5062-5071 PMID: 39110988 PMCID: PMC11459902 SCOPUS ID: 2-s2.0-85206247561 08/07/2024
Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma.

(Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri CJ, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo RD, Nadeem O, Mann H, Kalariya N, Hovanky V, DeAvila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr MM, Htut M, McGuirk JP, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK.) Blood. 2024 Oct 04 PMID: 39365257 10/04/2024
Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.

(Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Dutt PS, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Patel K, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D.) Clin Cancer Res. 2024 Oct 01;30(19):4542 PMID: 39350638 PMCID: PMC11443237 SCOPUS ID: 2-s2.0-85205446162 10/01/2024
Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers.

(Schinke C, Dhakal B, Mazzoni S, Shenoy S, Scott SA, Richards T, Le HH, DeBrosse A, Okorozo P, McDowell R, Patel S, Bunn J, Hawks K, Zhang X, Rodriguez C.) Curr Med Res Opin. 2024 Oct;40(10):1705-1711 PMID: 39177290 SCOPUS ID: 2-s2.0-85201809794 08/23/2024
Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell Transplantation.

(Akhtar OS, Arshad S, Lian Q, Ahn KW, D'Souza A, Dhakal B, Mohan M, Pasquini M, Longo W, Shah NN, Fenske TS, Hamadani M.) Transplant Cell Ther. 2024 Sep 18 PMID: 39303985 SCOPUS ID: 2-s2.0-85206435293 09/21/2024
Racial and Ethnic Disparities in Autologous Hematopoietic Cell Transplantation Utilization in Multiple Myeloma Have Persisted Over Time Even After Referral to a Transplant Center.

(Wu JF, Estrada-Merly N, Dhakal B, Mohan M, Narra RK, Pasquini MC, D'Souza A.) Transplant Cell Ther. 2024 Sep 12 PMID: 39277111 SCOPUS ID: 2-s2.0-85205846893 09/15/2024
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies.

(Akhtar OS, Szabo A, Bhatlapenumarthi V, Forsberg M, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Patel T, Shrestha A, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, Shah MR, Bag A, D'Souza A, Schinke C, Chakraborty R, Shah N, Mohan M.) Br J Haematol. 2024 Aug 27 PMID: 39192546 SCOPUS ID: 2-s2.0-85202177578 08/28/2024
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma.

(Chakraborty R, Cheruvalath H, Patwari A, Szabo A, Schinke C, Dhakal B, Lentzsch S, D'Souza A, Mohyuddin GR, Julian K, Midha S, Costello P, Kaiser M, Hing MNL, Harrison SJ, Cliff ERS, Mohan M.) Blood Cancer J. 2024 Aug 12;14(1):137 PMID: 39134535 PMCID: PMC11319778 SCOPUS ID: 2-s2.0-85201250452 08/13/2024
Plain language summary of the CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.

(San-Miguel J, Dhakal B, Patel N, Schecter JM, Lendvai N, Einsele H.) Future Oncol. 2024;20(33):2509-2520 PMID: 39110421 PMCID: PMC11537292 SCOPUS ID: 2-s2.0-85200761365 08/07/2024
Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma.

(Hansen DK, Dhakal B, Hamadani M, Dingli D, Jain T, Huff CA, Janakiram M, Liu YH, De Braganca KC, Lodowski N, Sander J, Okorozo P, McFarland L, Perciavalle M, Huo S, Qureshi ZP, Patel KK.) Front Immunol. 2024;15:1405452 PMID: 38915401 PMCID: PMC11194690 SCOPUS ID: 2-s2.0-85196643451 06/25/2024